Juno Therapeutics’ May 2015 acquisition of Stage Cell Therapeutics was not a $59 million all-in purchase. Juno paid about $59 million in cash up front, issued 486,279 shares, and agreed to as much as €135 million in milestone payments. It bought capabilities for selecting, activating, and manufacturing therapeutic cells—not a proven cancer treatment. Juno’s cash use should be assessed from its cash-flow statement, not inferred from its accumulated deficit.
What Juno bought, and when
Juno entered into and closed the acquisition on May 11, 2015, buying the Stage equity it did not already own. Juno had held about 5% of Stage; its later accounting identified that prior interest as 4.76%. Stage, based in Göttingen and Munich, Germany, developed technology platforms for cell therapies, including novel reagents and automation technology. Juno was developing cancer treatments using CAR and high-affinity T-cell receptor therapies.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Biotechnology | $103.82 | Buy on Amazon |
| 2 |
|
Basic Laboratory Methods for Biotechnology: Textbook and Laboratory Reference | $95.33 | Buy on Amazon |
| 3 |
|
Introduction to Biotechnology, Global Edition | $70.00 | Buy on Amazon |
| 4 |
|
Biotechnology: The Technological Applications of Genetics and Genomics | $141.90 | Buy on Amazon |
| 5 |
|
Introduction to Biotechnology (What's New in Biology) | $242.49 | Buy on Amazon |
The strategic fit was manufacturing and process development. Juno said Stage’s capabilities could give it cell selection and activation tools, next-generation manufacturing automation, greater supply-chain control, and lower expected long-term cost of goods. Those were anticipated benefits at the time, not demonstrated savings or proof of clinical success.
How much did the deal cost?
The headline’s approximately $59 million refers to the cash paid up front. It is only one part of the transaction. The filing reports €52.5 million in cash and 486,279 Juno common shares, plus up to €135 million in additional cash if specified milestones were met. Juno’s subsequent FY2015 accounting reported the cash as $58.5 million and valued the issued shares at $22.2 million.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →#1 Best Overall
| Transaction measure | Reported amount | What it means |
|---|---|---|
| Upfront cash | €52.5 million; later FY2015 accounting reported $58.5 million | Cash paid at closing, not the whole potential price. |
| Juno shares issued | 486,279 shares; later accounting valued them at $22.2 million | Noncash consideration in addition to the upfront cash. |
| Maximum milestone payments | Up to €135 million | Contingent cash, tied to technical, clinical, regulatory, and commercial milestones: €40 million for novel reagents, €65 million for advanced automation technology, and €30 million for Stage’s existing clinical pipeline. |
| Acquisition-date fair value of contingent consideration | $28.2 million | Juno’s accounting estimate of the contingent consideration’s fair value at acquisition; it is not the maximum earn-out. |
| Implied consideration for 100% of Stage | $112.6 million | Juno’s acquisition accounting, including the fair value of its pre-existing 4.76% interest; it is not simply the amount paid for the remaining stake. |
The amounts answer different questions: cash paid up front, stock issued, the maximum possible milestone payments, and accounting consideration for all of Stage are not interchangeable. The $112.6 million figure is an acquisition-accounting measure; it should not be read as cash spent at closing.
Why Stage’s capabilities mattered
Stage’s platforms included cell isolation and expansion technology using reversible reagents during T-cell manufacturing, according to Juno’s contemporaneous announcement. The company said Stage had 23 scientists, engineers, and other personnel. The acquisition offered Juno an opportunity to bring process development and manufacturing expertise closer to its therapy programs.
Juno CEO Hans Bishop said the acquisition was driven by a strategy to build “best in class process development and manufacturing capabilities” in support of its CAR and TCR programs. That statement describes Juno’s rationale; it does not establish that the deal subsequently reduced costs, improved outcomes, or produced an approved treatment.
What Juno’s deficit does—and does not—say about cash burn
Juno’s FY2015 Form 10-K reported an accumulated deficit of $585.7 million as of December 31, 2015. An accumulated deficit is a cumulative accounting balance, not the amount of cash the company used in 2015. Juno said the balance included noncash deemed dividends, technology-acquisition fees paid partly in cash and partly in stock, and noncash expense related to remeasurement and elapsed service of success-payment liabilities.
Free tools Windows power users keep installed
One-click scans. No signup required.
Rank #3
To answer how much cash Juno used in a particular year, use the cash-flow statement’s “net cash used in operating activities” for that period. Net loss is an income-statement measure, while accumulated deficit builds over time; neither should be substituted for operating cash flow. The stated $585.7 million deficit alone does not establish Juno’s 2015 operating cash burn.
Heavy research and development spending is common for companies developing therapies before they have products generating revenue, but spending does not predict whether a candidate will work. Juno’s filing identified risks including clinical-trial failure, obtaining marketing approval, commercialization, and securing adequate additional funding.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Later context: Celgene’s 2018 agreement
This was not part of the May 2015 acquisition story, but it is relevant later history: Celgene’s FY2017 annual report says it entered a merger agreement with Juno on January 21, 2018, at $87 per share in cash. Celgene described the transaction as approximately $9 billion net of cash and marketable securities acquired and Juno shares already owned by Celgene. That later agreement does not change what Juno paid for Stage in 2015.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
